Sage Therapeutics Inc (SAGE) - צמיחת רווח נקי למניה אחת לשנה הנוכחית

Sage Therapeutics, Inc. (SAGE) leads in the treatment of postpartum depression, capturing a growing segment of GABA modulators. The proportional EPS growth compared to last year, as tracked by the GURU.Markets platform, shows that the current parameter equals 46.40. Business stability is based on a partnership with Biogen, while the operating model relies on delegating trials to external CROs under strict management control.
פילוחי מדדים פיננסיים ומדדי שוק עבור sagerx.com (SAGE)

Slow market penetration of depression treatments and high commercial expenses at Sage Therapeutics, Inc. (SAGE) directly impact net income. EPS dynamics are calculated as the percentage deviation of the current earnings per share from the same period last year, quantifying the efficiency of operational management. Analyzing the annual EPS range allows for a distinction between genuine business growth and one-time cost reductions.